Corix Bioscience, Inc. Announces Joint Venture with ChampRX
19 January 2018 - 1:10AM
InvestorsHub NewsWire
Irvine, CA -- January 18, 2018 -- InvestorsHub NewsWire --
Corix Bioscience Inc. (OTCQB: CXBS) today announced that it will
joint venture with ChampRX for its products. Corix will provide
ChampRX with a 100% THC free product focused on athletes. Corix
will be their official CBD manufacturer and a 25% equity holder in
ChampRX. Both companies will be ring sponsors for Shannon Briggs’s
next title fight. Corix will also have access to the marketing for
ChampRX and its partners. Under the terms of the agreement, Corix
will provide the science and manufacturing behind the products and
ChampRX will market and promote the product.
The World Anti-Doping Agency (WADA) recently decided to remove
cannabidiol (CBD) from its list of banned substances in 2018.
“The recent WADA decision has opened up a large market of
athletes. Being able to produce a THC free product on a consistent
basis is our strength and vital to these athletes. The strong
benefits of non-THC based CBD oil can now be exploited. This will
be the first of many deals in the athletic arena. We have a number
of upcoming meetings with other large athletic organizations, which
should generate a number of new contracts,” commented Michael
Ogburn, Corix Bioscience CEO.
"The Prohibited List review involves a very extensive
stakeholder consultation process over the course of nine months,"
said Olivier Higgli, Director General, in an official statement.
"In reviewing the List, experts examine such sources as: scientific
and medical research; trends; and, intelligence gathered from law
enforcement and pharmaceutical companies in order to stay ahead of
those that endeavor to cheat the system."
While CBD will be permitted next year, the WADA notes that CBD
extracted from the cannabis plant may also contain varying
concentrations of tetrahydrocannabinol (THC), which remains a
prohibited substance. This means that athletes will need to
exercise extreme caution when taking CBD products to ensure that
they contain zero trace of THC. Extensive drug testing will be in
place to ensure that there are no trace amounts of the banned
psychoactive cannabinoid.
In 2015, the WADA tested over 300,000 athletes worldwide with
around 4% showing signs of cannabinoids in their system, which
under previous regulations included CBD and would automatically
disqualify any athlete testing positive. Under the new regulations,
even trace amounts of THC could disqualify athletes, which makes it
important to ensure that any CBD products consumed contain
absolutely no THC content.
The marketing of the products will begin immediately with
several telephone and print interviews during the remainder of the
month. This will include major athletic publications and
national TV networks.
“This is an exciting partnership for our company. This industry
is accelerating very quickly. When we couple our unique science
with the notoriety of the principals at ChampRX we will be able to
generate sizeable sales beginning almost immediately. Our goal is
to become the leading distributor and tissue culture propagator of
CBD in the world and this is another big step in that
direction. Our biggest competitive advantages of strong
genetic engineering, unsurpassed purity and worldwide industry
licenses will allow us to scale our operations very quickly,”
stated Ogburn.
About ChampRX
ChampRX is a company composed of several current and former
boxers. This includes many title holders including 2X Heavyweight
Champion Shannon Briggs, 2X Heavyweight Champion Chris Byrd with
several other Olympic and Boxing Champions including Lamon
Brewster, Montell Griffin and Ray Mercer, each multiple boxing
champion. For more information visit their website at
ChampRXCBD.com.
“This is a passion of mine and want to share this wonderful
plant with other fellow athletes that may be in the same place I
was. CBD saved my life. We wanted to combine forces with Corix to
develop a THC free, CBD product line that athletes can take without
worrying about failing a drug test. Corix hit it perfectly and we
are honored to have them as a partner,” says Shannon Briggs, 2X
Heavyweight Champion and Co-Owner of ChampRX.
See Shannon’s story;
https://hightimes.com/sports/boxing-champion-shannon-briggs-says-cannabis-saved-life/
About Corix Bioscience Inc.
Corix Bioscience Inc. ("Corix") is a Wyoming corporation and is
fully reporting with the SEC and is listed as OTCQB:
CXBS. Corix is the developer of proprietary cannabis and
industrial hemp strains using tissue cell cultures to propagate
living plants, with plans to patent the strains to be used in the
pharmaceutical medical industries.
Our methods allow us to create and breed new and existing plant
strains from tissue cells free of any pathogens or disease. We grow
these plants to maturity and extract the oils which are the
"medicine" part of the plant. Our sales are focused towards the
medical industry and we are developing brand named products to be
released in early 2018.
Corix's headquarters is located in Phoenix, Arizona with
laboratory and processing facility in Carson City, Nevada and
fields for growing the plants in Genoa, Nevada. We are
currently looking at expanding our footprint into Washington,
Oregon, California and Arizona. The Company's mission is to create
clean and consistent products in medical grade
facilities. Consistency being the key which will ultimately
yield a safer and superior product, better for people and the
environment. For more information, please visit Corix's website
at www.corixbioscience.com
Forward Looking Statement
This press release, and those statements regarding IXB and the
Company, contain forward-looking statements that relate to
expectations, beliefs, projections, future plans and strategies,
anticipated events and similar expressions. Forward-looking
statements may be identified by use of words such as "may," "will,"
"should," "expects," "intends," "plans," "anticipates," "believes,"
"estimates," or "potential" or similar words or phrases which are
predictions of or indicate future events or trends. Statements such
as those concerning potential acquisition activity, investment
objectives, strategies, opportunities, other plans and objectives
for future operations or economic performance are based on the
Company's current expectations, plans, estimates, assumptions and
beliefs that involve numerous risks and uncertainties. You are
cautioned not to place undue reliance on any forward-looking
statements and the Company disclaims any obligation to publicly
update or revise any forward-looking statement to reflect changes
in underlying assumptions or factors, new information, future
events or other changes. Please refer to Company's filings with the
Securities and Exchange Commission for further
information.
Corix Bioscience Inc. Christ Froese 623-551-5808 CFroese@CorixBioscience.com Brokers and Analysts Chesapeake Group 410-825-3930
Corix Bioscience (CE) (USOTC:CXBS)
Historical Stock Chart
From Oct 2024 to Nov 2024
Corix Bioscience (CE) (USOTC:CXBS)
Historical Stock Chart
From Nov 2023 to Nov 2024